Aethlon Medical to Present at The Wall Street Analyst Forum

         Aethlon Medical to Present at The Wall Street Analyst Forum

PR Newswire

SAN DIEGO, June 17, 2014

SAN DIEGO, June 17, 2014 /PRNewswire/ --Aethlon Medical, Inc. (OTCQX:AEMD),
the pioneer in developing selective therapeutic filtration devices to address
infectious disease, cancer and other life-threatening conditions, announced
today that the Company's Chairman and Chief Executive Officer, Jim Joyce, will
present at The Wall Street Analyst Forum 25^th Annual Institutional Investor
Conference on Thursday, June 19^th, at 12:05 PM EDT. Mr. Joyce's presentation
will include an update on a forthcoming FDA-cleared study of the Aethlon
Hemopurifier®, a review of the Company's cancer programs, and a progress
report on Exosome Sciences, Inc., a diagnostic subsidiary recently launched by
the Company.

Aethlon Hemopurifier

A live webcast of Mr. Joyce's Wall Street Analyst Forum presentation can be
accessed at the following URL: www.visualwebcaster.com/event.asp?id=99587

The Wall Street Analyst Forum will take place June 19, 2014 at the University
Club of New York, One West 54th Street, New York, NY.

About Aethlon Medical

Aethlon Medical creates innovative medical devices to address life-threatening
diseases. The Aethlon ADAPT™ (Adaptive Dialysis-like Affinity Platform
Technology) establishes the basis for a new class of therapeutics that target
the rapid elimination of disease enabling particles from the circulatory
system of treated patients. The lead Aethlon ADAPT™ product is the
Hemopurifier®, a device that addresses a broad-spectrum of viral pathogens as
well as tumor-secreted exosomes that suppress the immune system of cancer
patients. Aethlon is also operating under two government contracts with the
Defense Advanced Research Projects Agency (DARPA) related the development of a
medical device to reduce the incidence of sepsis. Exosome Sciences, Inc. is a
majority owned Aethlon subsidiary that is advancing exosome-based strategies
to diagnose and monitor cancer and infectious disease progression. Additional
information can be found at www.AethlonMedical.com

About The Wall Street Analyst Forum

The Wall Street Analyst Forum has conducted 80+ multiday/multitrack analyst
conferences in which over 2500 different NYSE/NASDAQ/AMEX/OTC companies have
presented and over 2,000 different institutions have attended in Boston, New
York and London since 1989. Public companies ranging from General Electric,
Microsoft Corp., Mattel Inc., Pfizer Inc., Kinross Gold to Genzyme have
presented. Institutions ranging from Fidelity Management, Wellington
Management, MFS Investment Management, Pioneer Investment Management, Putnam
Management have attended.

Certain statements herein may be forward-looking and involve risks and
uncertainties. Such forward-looking statements involve assumptions, known and
unknown risks, uncertainties and other factors which may cause the actual
results, performance or achievements of Aethlon Medical, Inc. to be materially
different from any future results, performance, or achievements expressed or
implied by the forward-looking statements. Such potential risks and
uncertainties include, without limitation, that the ESI will not be able to
commercialize its future products, that the FDA will not approve the
initiation of the Company's clinical programs or provide market clearance of
the company's products, future human studies whether revenue or non-revenue
generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an
adjunct therapy to improve patient responsiveness to established cancer or
hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the
Company's ability to raise capital when needed, the Company's ability to
complete the development of its planned products, the Company's ability to
manufacture its products either internally or through outside companies and
provide its services, the impact of government regulations, patent protection
on the Company's proprietary technology, the ability of the Company to meet
the milestones contemplated in the DARPA contract, product liability exposure,
uncertainty of market acceptance, competition, technological change, and other
risk factors. In such instances, actual results could differ materially as a
result of a variety of factors, including the risks associated with the effect
of changing economic conditions and other risk factors detailed in the
Company's Securities and Exchange Commission filings. The Company undertakes
no obligation to publicly update or revise any forward-looking statements,
whether as a result of new information, future events, or otherwise.

Contacts:

James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com

Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com

Marc Robins
877.276.2467
mr@aethlonmedical.com

ESI Logo

Photo - http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b
Logo - http://photos.prnewswire.com/prnh/20130912/LA78266LOGO

SOURCE Aethlon Medical, Inc.

Website: http://www.aethlonmedical.com
 
Press spacebar to pause and continue. Press esc to stop.